Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Current pharmacotherapy of Parkinson’s disease (PD) is symptomatic and palliative, with levodopa/carbidopa therapy remaining the prime treatment, and nevertheless, being unable to modulate the progression of the neurodegeneration. No available treatment for PD can enhance the patient’s life-quality...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6235 |
| _version_ | 1797555258093731840 |
|---|---|
| author | Tapan Behl Gagandeep Kaur Simona Bungau Rishabh Jhanji Arun Kumar Vineet Mehta Gokhan Zengin Roxana Brata Syed Shams ul Hassan Ovidiu Fratila |
| author_facet | Tapan Behl Gagandeep Kaur Simona Bungau Rishabh Jhanji Arun Kumar Vineet Mehta Gokhan Zengin Roxana Brata Syed Shams ul Hassan Ovidiu Fratila |
| author_sort | Tapan Behl |
| collection | DOAJ |
| description | Current pharmacotherapy of Parkinson’s disease (PD) is symptomatic and palliative, with levodopa/carbidopa therapy remaining the prime treatment, and nevertheless, being unable to modulate the progression of the neurodegeneration. No available treatment for PD can enhance the patient’s life-quality by regressing this diseased state. Various studies have encouraged the enrichment of treatment possibilities by discovering the association of the effects of the endocannabinoid system (ECS) in PD. These reviews delineate the reported evidence from the literature on the neuromodulatory role of the endocannabinoid system and expression of cannabinoid receptors in symptomatology, cause, and treatment of PD progression, wherein cannabinoid (CB) signalling experiences alterations of biphasic pattern during PD progression. Published papers to date were searched via MEDLINE, PubMed, etc., using specific key words in the topic of our manuscript. Endocannabinoids regulate the basal ganglia neuronal circuit pathways, synaptic plasticity, and motor functions via communication with dopaminergic, glutamatergic, and GABAergic signalling systems bidirectionally in PD. Further, gripping preclinical and clinical studies demonstrate the context regarding the cannabinoid compounds, which is supported by various evidence (neuroprotection, suppression of excitotoxicity, oxidative stress, glial activation, and additional benefits) provided by cannabinoid-like compounds (much research addresses the direct regulation of cannabinoids with dopamine transmission and other signalling pathways in PD). More data related to endocannabinoids efficacy, safety, and pharmacokinetic profiles need to be explored, providing better insights into their potential to ameliorate or even regress PD. |
| first_indexed | 2024-03-10T16:44:52Z |
| format | Article |
| id | doaj.art-658cdd4619964e54ab218a35b3251b61 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:44:52Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-658cdd4619964e54ab218a35b3251b612023-11-20T11:44:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117623510.3390/ijms21176235Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic InterventionsTapan Behl0Gagandeep Kaur1Simona Bungau2Rishabh Jhanji3Arun Kumar4Vineet Mehta5Gokhan Zengin6Roxana Brata7Syed Shams ul Hassan8Ovidiu Fratila9Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, IndiaDepartment of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, RomaniaNational Agri Food Biotechnology Institute, Mohali, Punjab 140306, IndiaDepartment of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab 140401, IndiaDepartment of Pharmacology, Government College of Pharmacy, Distt. Shimla, Himachal Pradesh, Rohru 171207, IndiaDepartment of Biology, Faculty of Science, Selcuk University Campus, 42130 Konya, TurkeyDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaShanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaDepartment of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, RomaniaCurrent pharmacotherapy of Parkinson’s disease (PD) is symptomatic and palliative, with levodopa/carbidopa therapy remaining the prime treatment, and nevertheless, being unable to modulate the progression of the neurodegeneration. No available treatment for PD can enhance the patient’s life-quality by regressing this diseased state. Various studies have encouraged the enrichment of treatment possibilities by discovering the association of the effects of the endocannabinoid system (ECS) in PD. These reviews delineate the reported evidence from the literature on the neuromodulatory role of the endocannabinoid system and expression of cannabinoid receptors in symptomatology, cause, and treatment of PD progression, wherein cannabinoid (CB) signalling experiences alterations of biphasic pattern during PD progression. Published papers to date were searched via MEDLINE, PubMed, etc., using specific key words in the topic of our manuscript. Endocannabinoids regulate the basal ganglia neuronal circuit pathways, synaptic plasticity, and motor functions via communication with dopaminergic, glutamatergic, and GABAergic signalling systems bidirectionally in PD. Further, gripping preclinical and clinical studies demonstrate the context regarding the cannabinoid compounds, which is supported by various evidence (neuroprotection, suppression of excitotoxicity, oxidative stress, glial activation, and additional benefits) provided by cannabinoid-like compounds (much research addresses the direct regulation of cannabinoids with dopamine transmission and other signalling pathways in PD). More data related to endocannabinoids efficacy, safety, and pharmacokinetic profiles need to be explored, providing better insights into their potential to ameliorate or even regress PD.https://www.mdpi.com/1422-0067/21/17/6235endocannabinoid systemendocannabinoidscannabinoid 1 receptorcannabinoid 2 receptorParkinson’s diseaseneuroprotection |
| spellingShingle | Tapan Behl Gagandeep Kaur Simona Bungau Rishabh Jhanji Arun Kumar Vineet Mehta Gokhan Zengin Roxana Brata Syed Shams ul Hassan Ovidiu Fratila Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions International Journal of Molecular Sciences endocannabinoid system endocannabinoids cannabinoid 1 receptor cannabinoid 2 receptor Parkinson’s disease neuroprotection |
| title | Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions |
| title_full | Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions |
| title_fullStr | Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions |
| title_full_unstemmed | Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions |
| title_short | Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions |
| title_sort | distinctive evidence involved in the role of endocannabinoid signalling in parkinson s disease a perspective on associated therapeutic interventions |
| topic | endocannabinoid system endocannabinoids cannabinoid 1 receptor cannabinoid 2 receptor Parkinson’s disease neuroprotection |
| url | https://www.mdpi.com/1422-0067/21/17/6235 |
| work_keys_str_mv | AT tapanbehl distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT gagandeepkaur distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT simonabungau distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT rishabhjhanji distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT arunkumar distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT vineetmehta distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT gokhanzengin distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT roxanabrata distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT syedshamsulhassan distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions AT ovidiufratila distinctiveevidenceinvolvedintheroleofendocannabinoidsignallinginparkinsonsdiseaseaperspectiveonassociatedtherapeuticinterventions |